# A Study to Evaluate The Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) in Healthy Population Aged 18 Years Old and Above

> **NCT04510207** · PHASE3 · COMPLETED · sponsor: **China National Biotec Group Company Limited** · enrollment: 44101 (actual)

## Conditions studied

- COVID-19

## Interventions

- **BIOLOGICAL:** Inactivated SARS-CoV-2 Vaccine (Vero cell)
- **BIOLOGICAL:** Inactivated SARS-CoV-2 Vaccine (Vero cell)
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT04510207
- **Lead sponsor:** China National Biotec Group Company Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-07-16
- **Primary completion:** 2021-06-16
- **Final completion:** 2021-12-31
- **Target enrollment:** 44101 (ACTUAL)
- **Last updated:** 2023-06-18

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04510207

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04510207, "A Study to Evaluate The Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) in Healthy Population Aged 18 Years Old and Above". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04510207. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*